Neurite outgrowth can be modulated in vitro using a tetracycline- repressible gene therapy vector expressing human nerve growth factor

Journal of Neuroscience Research

Volumn 59, Issue 3, 2000, Pages 402-409

  Blesch, Armin ^a   Uy, Hua S ^a   Diergardt, Nicole ^a   Tuszynski, Mark H ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Gene therapy; NGF; Regeneration; Regulatable expression; Retrovirus; Spinal cord injury; Tetracycline

Indexed keywords

COMPLEMENTARY DNA; DOXYCYCLINE; GREEN FLUORESCENT PROTEIN; MESSENGER RNA; NERVE GROWTH FACTOR; TETRACYCLINE; VIRUS VECTOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOSE RESPONSE; FIBROBLAST CULTURE; GENE EXPRESSION REGULATION; GENE THERAPY; NERVE FIBER GROWTH; NERVE REGENERATION; NONHUMAN; PRIORITY JOURNAL; RAT; RETROVIRUS; SPINAL CORD INJURY;

ANIMALS; ANTI-BACTERIAL AGENTS; CELLS, CULTURED; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; LUMINESCENT PROTEINS; NERVE GROWTH FACTOR; NEURITES; RATS; RATS, INBRED F344; TETRACYCLINE; TRANSFECTION;

EID: 0034141674     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4547(20000201)59:3<402::AID-JNR14>3.0.CO;2-Q     Document Type: Article

References (45)

1. Blesch A, Diergardt N, Tuszynski MH. 1998a. Cellularly delivered GDNF induces robust growth of motor and sensory axons in the injured adult spinal cord. Soc Neurosci Abstr 24:555.
2. Blesch A, Grill RJ, Tuszynski MH. 1998b. Neurotrophin gene therapy in CNS models of trauma and degeneration. Progr Brain Res 117: 473-484.
3. Blesch A, Tuszynski MH. 1995. Ex vivo gene therapy for Alzheimer's disease and spinal cord injury. Clin Neurosci 3:268-274.
4. Blesch A, Uy HS, Grill RJ, Cheng JG, Patterson PH, Tuszynski MH. 1999. LIF augments corticospinal axon growth and neurotrophin expression after adult CNS injury. J Neurosci 19:3556-3566.
5. Bohl D, Naffakh N, Heard JM. 1997. Long-term control of erythropoietin secretion by doxycycline in mice transplanted with engineered primary myoblasts. Nat Med 3:299-305.
6. Conner JM, Varon S. 1996. Characterization of antibodies to nerve growth factor: assay-dependent variability in the cross-reactivity with other neurotrophins. J Neurosci Meth 65:93-99.
7. Corti O, Horellou P, Colin P, Cattaneo E, Mallet J. 1996. Intracerebral tetracycline-dependent regulation of gene expression in grafts of neural precursors. NeuroReport 7:1655-1659.
8. Delort JP, Capecchi MR. 1996. TAXI/UAS: a molecular switch to control expression of genes in vivo. Hum Gene Ther 7:809-820.
9. Eide FF, Lowenstein DH, Reichardt LF. 1993. Neurotrophins and their receptors - current concepts and implications for neurologic disease. Exp Neurol 121:200-214.
10. Fisher LJ, Ray J. 1994. In vivo and ex vivo gene transfer to the brain. Curr Opin Neurobiol 4:735-741.
11. Furth PA, St OL, Boger H, Gruss P, Gossen M, Kistner A, Bujard H, Hennighausen L. 1994. Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. Proc Natl Acad Sci USA 91:9302-9306.
12. Gage FH, Rosenberg MB, Tuszynski MH, Yoshida K, Armstrong DM, Hayes RC, Friedmann T. 1990. Gene therapy in the CNS: intracerebral grafting of genetically modified cells. Prog Brain Res 86:205-217.
13. Gage FH, Wolff JA, Rosenberg MB, Xu L, Yee JK, Shults C, Friedmann T. 1987. Grafting genetically modified cells to the brain: possibilities for the future. Neuroscience 23:795-807.
14. Gossen M, Bonin AL, Bujard H. 1993. Control of gene activity in higher eukaryotic cells by prokaryotic regulatory elements. Trends Biochem Sci 18:471-475.
15. Gossen M, Bujard H. 1992. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 89:5547-5551.
16. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H. 1995. Transcriptional activation by tetracyclines in mammalian cells. Science 268:1766-1769.
17. Grill R, Murai K, Blesch A, Gage FH, Tuszynski MH. 1997a. Cellular delivery of neurotrophin-3 promotes corticospinal axonal growth and partial functional recovery after spinal cord injury. J Neurosci 17:5560-5572.
18. Grill RJ, Blesch A, Tuszynski MH. 1997b. Robust growth of chronically injured spinal cord axons induced by grafts of genetically modified NGF-secreting cells. Exp Neurol 148:444-452.
19. Kistner A, Gossen M, Zimmermann F, Jerecic J, Ullmer C, Lubbert H, Bujard H. 1996. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci USA 93:10933-10938.
20. Lindsay RM, Wiegand SJ, Altar CA, DiStefano PS. 1994. Neurotrophic factors: from molecule to man. Trends Neurosci 17:182-190.
21. Liu Y, Kim D, Himes BT, Chow SY, Schallert T, Murray M, Tessler A, Fischer I. 1999. Transplants of fibroblasts genetically modified to express brain-derived neurotrophic factor promote regeneration of adult rat rubrospinal axons and recovery of forelimb function. J Neurosci 19: 4370-4387.
22. Magari SR, Rivera VM, Iuliucci JD, Gilman M, Cerasoli F, Jr. 1997. Pharmacologic control of a humanized gene therapy system implanted into nude mice. J Clin Invest 100:2865-2872.
23. Miller AD. 1990. Retrovirus packaging cells. Hum Gene Ther 1:5-14.
24. Miller AD, Miller DG, Garcia JV, Lynch CM. 1993. Use of retroviral vectors for gene transfer and expression. Methods Enzymol 217:581-599.
25. Miller AD, Palmer TD, Hock RA. 1986. Transfer of genes into human somatic cells using retrovirus vectors. Cold Spring Harb Symp Quant Biol 51:1013-1019.
26. Nakahara Y, Gage FH, Tuszynski MH. 1996. Graft of fibroblasts genetically modified to secrete NGF, BDNF, NT-3, or basic FGF elicit differential responses in the adult spinal cord. Cell Transplant 5:191-204.
27. No D, Yao TP, Evans RM. 1996. Ecdysone-inducible gene expression in mammalian cells and transgenic mice. Proc Natl Acad Sci USA 93:3346-3351.
28. Pear WS, Scott ML, Nolan GP. 1997. Generation of high-titer, helper-free retroviruses by transient transfection. In: Robbins PD, editor. Methods in molecular medicine: gene therapy protocols. Totowa, New Jersey: Humana Press Inc. p 41-57.
29. Raymon HK, Thode S, Gage FH. 1997. Application of ex vivo gene therapy in the treatment of Parkinson's disease. Exp Neurol 144:82-91.
30. Rivera VM, Clackson T, Natesan S, Pollock R, Amara JF, Keenan T, Magari SR, Phillips T, Courage NL, Cerasoli F, Jr., Holt DA, Gilman M. 1996. A humanized system for pharmacologic control of gene expression. Nat Med 2:1028-1032.
31. Rossi FM, Blau HM. 1998. Recent advances in inducible gene expression systems. Current Opin Biotechnol 9:451-456.
32. Rukenstein A, Greene LA. 1983. The quantitative bioassay of nerve growth factor: use of frozen 'primed' PC12 pheochromocytoma cells. Brain Res 263:177-180.
33. Shockett P, Difilippantonio M, Hellman N, Schatz DG. 1995. A modified tetracycline-regulated system provides autoregulatory, inducible gene expression in cultured cells and transgenic mice. Proc Natl Acad Sci USA 92:6522-6526.
34. Suhr ST, Gage FH. 1993. Gene therapy for neurologic disease. Arch Neurol 50:1252-1268.
35. Suhr ST, Gil EB, Senut MC, Gage FH. 1998. High level transactivation by a modified Bombyx ecdysone receptor in mammalian cells without exogenous retinoid X receptor. Proc Natl Acad Sci USA 95:7999-8004.
36. Tuszynski M, Grill R, Blesch A. 1999. Spinal cord regeneration. In: Tuszynski M, Kordower J, editors. CNS regeneration: basic science and clinical applications. San Diego: Academic Press. p 605-630.
37. Tuszynski MH, Gabriel K, Gage FH, Suhr S, Meyer S, Rosetti A. 1996. Nerve growth factor delivery by gene transfer induces differential outgrowth of sensory, motor, and noradrenergic neurites after adult spinal cord injury. Exp Neurol 137:157-173.
38. Tuszynski MH, Gage FH. 1994. Neurotrophic factors and diseases of the nervous system. Ann Neurol 35(suppl):S9-12.
39. Tuszynski MH, Gage FH. 1996. Somatic gene therapy for nervous system disease. CIBA Found Symp 196:85-94.
40. Tuszynski MH, Murai K, Blesch A, Grill R, Miller I. 1997. Functional characterization of NGF-secreting cell grafts to the acutely injured spinal cord. Cell Transplant 6:361-368.
41. Tuszynski MH, Peterson DA, Ray J, Baird A, Nakahara Y, Gage FH. 1994a. Fibroblasts genetically modified to produce nerve growth factor induce robust neuritic ingrowth after grafting to the spinal cord. Exp Neurol 126:1-14.
42. Tuszynski MH, Senut MC, Ray J, Roberts J. 1994b. Somatic gene transfer to the adult primate central nervous system: in vitro and in vivo characterization of cells genetically modified to secrete nerve growth factor. Neurobiol Dis 1:67-78.
43. Weidner N, Blesch A, Grill R, Tuszynski M. 1999. Nerve growth factor-hypersecreting Schwann cell grafts augment and guide spinal cord axonal growth and remyelinate central nervous system axons in a phenotypically appropriate manner that correlates with expression of L1. J Comp Neurol 413:495-506.
44. Winkler J, Ramirez GA, Kuhn HG, Peterson DA, Day-Lollini PA, Stewart GR, Tuszynski MH, Gage FH, Thal LJ. 1997. Reversible Schwann cell hyperplasia and sprouting of sensory and sympathetic neurites after intraventricular administration of nerve growth factor. Ann Neurol 41:82-93.
45. Ye X, Rivera VM, Zoltick P, Cerasoli F, Jr., Schnell MA, Gao G, Hughes JV, Gilman M, Wilson JM. 1999. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science 283:88-91.